nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—Leukaemia—Hydroxyurea—head and neck cancer	0.0243	0.0606	CcSEcCtD
Pimecrolimus—Application site burn—Fluorouracil—head and neck cancer	0.0225	0.056	CcSEcCtD
Pimecrolimus—Skin atrophy—Hydroxyurea—head and neck cancer	0.0217	0.054	CcSEcCtD
Pimecrolimus—Skin cancer—Hydroxyurea—head and neck cancer	0.0211	0.0526	CcSEcCtD
Pimecrolimus—Superinfection—Fluorouracil—head and neck cancer	0.0208	0.0517	CcSEcCtD
Pimecrolimus—Skin hyperpigmentation—Hydroxyurea—head and neck cancer	0.011	0.0274	CcSEcCtD
Pimecrolimus—Application site pain—Fluorouracil—head and neck cancer	0.0107	0.0267	CcSEcCtD
Pimecrolimus—Application site reaction—Fluorouracil—head and neck cancer	0.0101	0.025	CcSEcCtD
Pimecrolimus—Skin hyperpigmentation—Fluorouracil—head and neck cancer	0.00793	0.0197	CcSEcCtD
Pimecrolimus—Skin exfoliation—Hydroxyurea—head and neck cancer	0.00626	0.0156	CcSEcCtD
Pimecrolimus—Skin hyperpigmentation—Docetaxel—head and neck cancer	0.00573	0.0143	CcSEcCtD
Pimecrolimus—Eye irritation—Fluorouracil—head and neck cancer	0.00553	0.0138	CcSEcCtD
Pimecrolimus—Herpes simplex—Fluorouracil—head and neck cancer	0.00512	0.0127	CcSEcCtD
Pimecrolimus—Throat sore—Docetaxel—head and neck cancer	0.00472	0.0118	CcSEcCtD
Pimecrolimus—Oropharyngeal discomfort—Docetaxel—head and neck cancer	0.00468	0.0117	CcSEcCtD
Pimecrolimus—Face oedema—Hydroxyurea—head and neck cancer	0.00459	0.0114	CcSEcCtD
Pimecrolimus—Otitis media—Docetaxel—head and neck cancer	0.00437	0.0109	CcSEcCtD
Pimecrolimus—Breast disorder—Hydroxyurea—head and neck cancer	0.0043	0.0107	CcSEcCtD
Pimecrolimus—Rhinorrhoea—Docetaxel—head and neck cancer	0.0042	0.0105	CcSEcCtD
Pimecrolimus—Eye irritation—Docetaxel—head and neck cancer	0.00399	0.00993	CcSEcCtD
Pimecrolimus—Swelling—Fluorouracil—head and neck cancer	0.00388	0.00966	CcSEcCtD
Pimecrolimus—Bone disorder—Docetaxel—head and neck cancer	0.00377	0.00938	CcSEcCtD
Pimecrolimus—Oropharyngeal pain—Docetaxel—head and neck cancer	0.00375	0.00932	CcSEcCtD
Pimecrolimus—Infestation—Hydroxyurea—head and neck cancer	0.00367	0.00913	CcSEcCtD
Pimecrolimus—Infestation NOS—Hydroxyurea—head and neck cancer	0.00367	0.00913	CcSEcCtD
Pimecrolimus—Pharyngitis—Vinblastine—head and neck cancer	0.00358	0.00892	CcSEcCtD
Pimecrolimus—MTOR—neck—head and neck cancer	0.00358	0.12	CbGeAlD
Pimecrolimus—Influenza like illness—Docetaxel—head and neck cancer	0.00331	0.00823	CcSEcCtD
Pimecrolimus—Skin exfoliation—Docetaxel—head and neck cancer	0.00325	0.00809	CcSEcCtD
Pimecrolimus—FKBP1A—neck—head and neck cancer	0.00322	0.108	CbGeAlD
Pimecrolimus—Nasopharyngitis—Fluorouracil—head and neck cancer	0.00306	0.00762	CcSEcCtD
Pimecrolimus—Erythema—Hydroxyurea—head and neck cancer	0.00287	0.00713	CcSEcCtD
Pimecrolimus—Swelling—Docetaxel—head and neck cancer	0.0028	0.00697	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00275	0.00685	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.0027	0.00673	CcSEcCtD
Pimecrolimus—Pneumonia—Fluorouracil—head and neck cancer	0.00265	0.00661	CcSEcCtD
Pimecrolimus—Infestation—Fluorouracil—head and neck cancer	0.00264	0.00657	CcSEcCtD
Pimecrolimus—Infestation NOS—Fluorouracil—head and neck cancer	0.00264	0.00657	CcSEcCtD
Pimecrolimus—Conjunctivitis—Fluorouracil—head and neck cancer	0.00257	0.00639	CcSEcCtD
Pimecrolimus—MTOR—connective tissue—head and neck cancer	0.00256	0.0858	CbGeAlD
Pimecrolimus—Epistaxis—Fluorouracil—head and neck cancer	0.00249	0.0062	CcSEcCtD
Pimecrolimus—Sinusitis—Fluorouracil—head and neck cancer	0.00248	0.00616	CcSEcCtD
Pimecrolimus—MTOR—epithelium—head and neck cancer	0.00243	0.0814	CbGeAlD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00242	0.00603	CcSEcCtD
Pimecrolimus—Rhinitis—Fluorouracil—head and neck cancer	0.00238	0.00591	CcSEcCtD
Pimecrolimus—Pharyngitis—Fluorouracil—head and neck cancer	0.00235	0.00585	CcSEcCtD
Pimecrolimus—Oedema—Hydroxyurea—head and neck cancer	0.00234	0.00582	CcSEcCtD
Pimecrolimus—Infection—Hydroxyurea—head and neck cancer	0.00232	0.00578	CcSEcCtD
Pimecrolimus—FKBP1A—connective tissue—head and neck cancer	0.00231	0.0772	CbGeAlD
Pimecrolimus—Paraesthesia—Vinblastine—head and neck cancer	0.0023	0.00573	CcSEcCtD
Pimecrolimus—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00229	0.00571	CcSEcCtD
Pimecrolimus—Skin disorder—Hydroxyurea—head and neck cancer	0.00227	0.00565	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Docetaxel—head and neck cancer	0.00226	0.00562	CcSEcCtD
Pimecrolimus—Breast disorder—Docetaxel—head and neck cancer	0.00223	0.00556	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Docetaxel—head and neck cancer	0.00221	0.0055	CcSEcCtD
Pimecrolimus—Pain—Vinblastine—head and neck cancer	0.00219	0.00546	CcSEcCtD
Pimecrolimus—Constipation—Vinblastine—head and neck cancer	0.00219	0.00546	CcSEcCtD
Pimecrolimus—FKBP1A—epithelium—head and neck cancer	0.00219	0.0732	CbGeAlD
Pimecrolimus—Gastrointestinal pain—Vinblastine—head and neck cancer	0.0021	0.00522	CcSEcCtD
Pimecrolimus—Dyspnoea—Hydroxyurea—head and neck cancer	0.00209	0.00519	CcSEcCtD
Pimecrolimus—Erythema—Fluorouracil—head and neck cancer	0.00206	0.00513	CcSEcCtD
Pimecrolimus—Abdominal pain—Vinblastine—head and neck cancer	0.00203	0.00505	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00202	0.00503	CcSEcCtD
Pimecrolimus—Constipation—Hydroxyurea—head and neck cancer	0.002	0.00498	CcSEcCtD
Pimecrolimus—Pain—Hydroxyurea—head and neck cancer	0.002	0.00498	CcSEcCtD
Pimecrolimus—FKBP1A—trachea—head and neck cancer	0.00194	0.0648	CbGeAlD
Pimecrolimus—Pneumonia—Docetaxel—head and neck cancer	0.00192	0.00477	CcSEcCtD
Pimecrolimus—Infestation—Docetaxel—head and neck cancer	0.00191	0.00474	CcSEcCtD
Pimecrolimus—Infestation NOS—Docetaxel—head and neck cancer	0.00191	0.00474	CcSEcCtD
Pimecrolimus—Hypersensitivity—Vinblastine—head and neck cancer	0.00189	0.0047	CcSEcCtD
Pimecrolimus—MTOR—lymphoid tissue—head and neck cancer	0.00188	0.0627	CbGeAlD
Pimecrolimus—Conjunctivitis—Docetaxel—head and neck cancer	0.00185	0.00461	CcSEcCtD
Pimecrolimus—Body temperature increased—Hydroxyurea—head and neck cancer	0.00185	0.0046	CcSEcCtD
Pimecrolimus—Epistaxis—Docetaxel—head and neck cancer	0.0018	0.00447	CcSEcCtD
Pimecrolimus—Diarrhoea—Vinblastine—head and neck cancer	0.00175	0.00437	CcSEcCtD
Pimecrolimus—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00172	0.00429	CcSEcCtD
Pimecrolimus—Rhinitis—Docetaxel—head and neck cancer	0.00171	0.00427	CcSEcCtD
Pimecrolimus—MTOR—thyroid gland—head and neck cancer	0.0017	0.057	CbGeAlD
Pimecrolimus—Pharyngitis—Docetaxel—head and neck cancer	0.0017	0.00422	CcSEcCtD
Pimecrolimus—FKBP1A—lymphoid tissue—head and neck cancer	0.00169	0.0564	CbGeAlD
Pimecrolimus—Oedema—Fluorouracil—head and neck cancer	0.00168	0.00419	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00168	0.00419	CcSEcCtD
Pimecrolimus—Infection—Fluorouracil—head and neck cancer	0.00167	0.00416	CcSEcCtD
Pimecrolimus—Nervous system disorder—Fluorouracil—head and neck cancer	0.00165	0.00411	CcSEcCtD
Pimecrolimus—Vomiting—Vinblastine—head and neck cancer	0.00163	0.00406	CcSEcCtD
Pimecrolimus—Headache—Vinblastine—head and neck cancer	0.00161	0.004	CcSEcCtD
Pimecrolimus—Diarrhoea—Hydroxyurea—head and neck cancer	0.0016	0.00398	CcSEcCtD
Pimecrolimus—Eye disorder—Docetaxel—head and neck cancer	0.0016	0.00398	CcSEcCtD
Pimecrolimus—Flushing—Docetaxel—head and neck cancer	0.00159	0.00395	CcSEcCtD
Pimecrolimus—Immune system disorder—Docetaxel—head and neck cancer	0.00154	0.00384	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Docetaxel—head and neck cancer	0.00154	0.00384	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00153	0.00382	CcSEcCtD
Pimecrolimus—FKBP1A—thyroid gland—head and neck cancer	0.00153	0.0512	CbGeAlD
Pimecrolimus—Nausea—Vinblastine—head and neck cancer	0.00152	0.00379	CcSEcCtD
Pimecrolimus—Paraesthesia—Fluorouracil—head and neck cancer	0.00151	0.00376	CcSEcCtD
Pimecrolimus—MTOR—head—head and neck cancer	0.00151	0.0505	CbGeAlD
Pimecrolimus—Dyspnoea—Fluorouracil—head and neck cancer	0.0015	0.00374	CcSEcCtD
Pimecrolimus—Erythema—Docetaxel—head and neck cancer	0.00149	0.00371	CcSEcCtD
Pimecrolimus—Malnutrition—Docetaxel—head and neck cancer	0.00149	0.00371	CcSEcCtD
Pimecrolimus—Vomiting—Hydroxyurea—head and neck cancer	0.00149	0.0037	CcSEcCtD
Pimecrolimus—Rash—Hydroxyurea—head and neck cancer	0.00147	0.00367	CcSEcCtD
Pimecrolimus—Dermatitis—Hydroxyurea—head and neck cancer	0.00147	0.00367	CcSEcCtD
Pimecrolimus—Headache—Hydroxyurea—head and neck cancer	0.00147	0.00365	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00145	0.00362	CcSEcCtD
Pimecrolimus—Back pain—Docetaxel—head and neck cancer	0.00144	0.00358	CcSEcCtD
Pimecrolimus—Pain—Fluorouracil—head and neck cancer	0.00144	0.00358	CcSEcCtD
Pimecrolimus—Nausea—Hydroxyurea—head and neck cancer	0.00139	0.00346	CcSEcCtD
Pimecrolimus—FKBP1A—head—head and neck cancer	0.00136	0.0455	CbGeAlD
Pimecrolimus—Urticaria—Fluorouracil—head and neck cancer	0.00134	0.00333	CcSEcCtD
Pimecrolimus—Body temperature increased—Fluorouracil—head and neck cancer	0.00133	0.00331	CcSEcCtD
Pimecrolimus—Cough—Docetaxel—head and neck cancer	0.0013	0.00323	CcSEcCtD
Pimecrolimus—Arthralgia—Docetaxel—head and neck cancer	0.00127	0.00315	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00126	0.00313	CcSEcCtD
Pimecrolimus—Hypersensitivity—Fluorouracil—head and neck cancer	0.00124	0.00309	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Docetaxel—head and neck cancer	0.00122	0.00302	CcSEcCtD
Pimecrolimus—Oedema—Docetaxel—head and neck cancer	0.00122	0.00302	CcSEcCtD
Pimecrolimus—Infection—Docetaxel—head and neck cancer	0.00121	0.003	CcSEcCtD
Pimecrolimus—Nervous system disorder—Docetaxel—head and neck cancer	0.00119	0.00297	CcSEcCtD
Pimecrolimus—Pruritus—Fluorouracil—head and neck cancer	0.00119	0.00296	CcSEcCtD
Pimecrolimus—Skin disorder—Docetaxel—head and neck cancer	0.00118	0.00294	CcSEcCtD
Pimecrolimus—Diarrhoea—Fluorouracil—head and neck cancer	0.00115	0.00287	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.00111	0.00276	CcSEcCtD
Pimecrolimus—Paraesthesia—Docetaxel—head and neck cancer	0.00109	0.00272	CcSEcCtD
Pimecrolimus—Dyspnoea—Docetaxel—head and neck cancer	0.00108	0.0027	CcSEcCtD
Pimecrolimus—Vomiting—Fluorouracil—head and neck cancer	0.00107	0.00266	CcSEcCtD
Pimecrolimus—Rash—Fluorouracil—head and neck cancer	0.00106	0.00264	CcSEcCtD
Pimecrolimus—Dermatitis—Fluorouracil—head and neck cancer	0.00106	0.00264	CcSEcCtD
Pimecrolimus—MTOR—lymph node—head and neck cancer	0.00106	0.0354	CbGeAlD
Pimecrolimus—Headache—Fluorouracil—head and neck cancer	0.00105	0.00262	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00105	0.00261	CcSEcCtD
Pimecrolimus—Constipation—Docetaxel—head and neck cancer	0.00104	0.00259	CcSEcCtD
Pimecrolimus—Pain—Docetaxel—head and neck cancer	0.00104	0.00259	CcSEcCtD
Pimecrolimus—Nausea—Fluorouracil—head and neck cancer	0.001	0.00249	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000994	0.00247	CcSEcCtD
Pimecrolimus—Abdominal pain—Docetaxel—head and neck cancer	0.000961	0.00239	CcSEcCtD
Pimecrolimus—Body temperature increased—Docetaxel—head and neck cancer	0.000961	0.00239	CcSEcCtD
Pimecrolimus—FKBP1A—lymph node—head and neck cancer	0.000952	0.0318	CbGeAlD
Pimecrolimus—Hypersensitivity—Docetaxel—head and neck cancer	0.000895	0.00223	CcSEcCtD
Pimecrolimus—Pruritus—Docetaxel—head and neck cancer	0.00086	0.00214	CcSEcCtD
Pimecrolimus—Diarrhoea—Docetaxel—head and neck cancer	0.000831	0.00207	CcSEcCtD
Pimecrolimus—Vomiting—Docetaxel—head and neck cancer	0.000773	0.00192	CcSEcCtD
Pimecrolimus—Rash—Docetaxel—head and neck cancer	0.000766	0.00191	CcSEcCtD
Pimecrolimus—Dermatitis—Docetaxel—head and neck cancer	0.000765	0.0019	CcSEcCtD
Pimecrolimus—Headache—Docetaxel—head and neck cancer	0.000761	0.00189	CcSEcCtD
Pimecrolimus—Nausea—Docetaxel—head and neck cancer	0.000722	0.0018	CcSEcCtD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—head and neck cancer	0.0007	0.00123	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—MAPK3—head and neck cancer	0.0007	0.00123	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—MAPK3—head and neck cancer	0.000688	0.00121	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—STAT6—head and neck cancer	0.000688	0.00121	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—PTEN—head and neck cancer	0.000683	0.0012	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—PTEN—head and neck cancer	0.000683	0.0012	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—PTEN—head and neck cancer	0.000683	0.0012	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—PIK3CA—head and neck cancer	0.00068	0.0012	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—HRAS—head and neck cancer	0.000677	0.00119	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—head and neck cancer	0.000677	0.00119	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—PTEN—head and neck cancer	0.000677	0.00119	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—PIK3CA—head and neck cancer	0.000675	0.00119	CbGpPWpGaD
Pimecrolimus—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000672	0.00118	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—PTEN—head and neck cancer	0.000671	0.00118	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—MAPK3—head and neck cancer	0.000669	0.00118	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—PTEN—head and neck cancer	0.000668	0.00117	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—head and neck cancer	0.000666	0.00117	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—MAPK1—head and neck cancer	0.000666	0.00117	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—EGFR—head and neck cancer	0.000666	0.00117	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—MAPK3—head and neck cancer	0.000659	0.00116	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—STAT3—head and neck cancer	0.000659	0.00116	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	0.000658	0.00116	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—STAT3—head and neck cancer	0.000655	0.00115	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—MAPK1—head and neck cancer	0.000655	0.00115	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—MAPK1—head and neck cancer	0.000637	0.00112	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—EGFR—head and neck cancer	0.000637	0.00112	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—MAPK3—head and neck cancer	0.000632	0.00111	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—PTEN—head and neck cancer	0.000632	0.00111	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—AKT1—head and neck cancer	0.000631	0.00111	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—MAPK1—head and neck cancer	0.00063	0.00111	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—head and neck cancer	0.00063	0.00111	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—MAPK3—head and neck cancer	0.000629	0.00111	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—HRAS—head and neck cancer	0.000629	0.00111	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—MAPK1—head and neck cancer	0.000627	0.0011	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—EGFR—head and neck cancer	0.000627	0.0011	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—MAPK3—head and neck cancer	0.000626	0.0011	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—HRAS—head and neck cancer	0.000625	0.0011	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—MAPK3—head and neck cancer	0.000623	0.0011	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—MAPK3—head and neck cancer	0.00062	0.00109	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—AKT1—head and neck cancer	0.000616	0.00108	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—AKT1—head and neck cancer	0.000611	0.00108	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—STAT3—head and neck cancer	0.000611	0.00107	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—YAP1—head and neck cancer	0.000609	0.00107	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PTEN—head and neck cancer	0.000605	0.00106	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—MAPK1—head and neck cancer	0.000602	0.00106	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—MAPK1—head and neck cancer	0.000599	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—EGFR—head and neck cancer	0.000599	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—STAT6—head and neck cancer	0.000598	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—head and neck cancer	0.000597	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—AKT1—head and neck cancer	0.000597	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—STAT3—head and neck cancer	0.000597	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—MAPK1—head and neck cancer	0.000596	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—MAPK1—head and neck cancer	0.000596	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—head and neck cancer	0.000596	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—EGFR—head and neck cancer	0.000596	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—MAPK1—head and neck cancer	0.000593	0.00104	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—EGFR—head and neck cancer	0.000593	0.00104	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—MAPK1—head and neck cancer	0.00059	0.00104	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—EGFR—head and neck cancer	0.00059	0.00104	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—AKT1—head and neck cancer	0.000588	0.00104	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—MAPK3—head and neck cancer	0.000583	0.00103	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—MAPK3—head and neck cancer	0.000583	0.00103	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MAPK3—head and neck cancer	0.000583	0.00103	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—head and neck cancer	0.000581	0.00102	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—MAPK3—head and neck cancer	0.000578	0.00102	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—PIK3CA—head and neck cancer	0.000578	0.00102	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—MAPK3—head and neck cancer	0.000573	0.00101	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—MAPK3—head and neck cancer	0.00057	0.001	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—AKT1—head and neck cancer	0.000555	0.000977	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MAPK1—head and neck cancer	0.000555	0.000977	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—MAPK1—head and neck cancer	0.000555	0.000977	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—MAPK1—head and neck cancer	0.000555	0.000977	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—EGFR—head and neck cancer	0.000555	0.000976	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—EGFR—head and neck cancer	0.000555	0.000976	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—head and neck cancer	0.000555	0.000976	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—PIK3CA—head and neck cancer	0.000553	0.000973	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—MAPK1—head and neck cancer	0.00055	0.000968	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—EGFR—head and neck cancer	0.00055	0.000968	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—MAPK1—head and neck cancer	0.000545	0.000959	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—EGFR—head and neck cancer	0.000545	0.000959	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—PIK3CA—head and neck cancer	0.000544	0.000957	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—MAPK1—head and neck cancer	0.000543	0.000955	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—EGFR—head and neck cancer	0.000543	0.000955	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—STAT3—head and neck cancer	0.000541	0.000952	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—HRAS—head and neck cancer	0.000534	0.00094	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—head and neck cancer	0.000529	0.000931	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—HRAS—head and neck cancer	0.000526	0.000925	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—PIK3CA—head and neck cancer	0.000522	0.000919	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—PIK3CA—head and neck cancer	0.00052	0.000914	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—PIK3CA—head and neck cancer	0.000517	0.00091	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—MAPK3—head and neck cancer	0.000517	0.000909	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—PIK3CA—head and neck cancer	0.000514	0.000905	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—EGFR—head and neck cancer	0.000514	0.000904	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—PIK3CA—head and neck cancer	0.000512	0.000901	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—HRAS—head and neck cancer	0.000511	0.0009	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—PIK3CA—head and neck cancer	0.000505	0.000888	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—HRAS—head and neck cancer	0.000503	0.000886	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—MAPK1—head and neck cancer	0.000492	0.000865	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—head and neck cancer	0.000491	0.000865	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KISS1—head and neck cancer	0.000484	0.000851	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—HRAS—head and neck cancer	0.000483	0.00085	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—PIK3CA—head and neck cancer	0.000482	0.000847	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—PIK3CA—head and neck cancer	0.000482	0.000847	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—PIK3CA—head and neck cancer	0.000482	0.000847	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—HRAS—head and neck cancer	0.000481	0.000846	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—head and neck cancer	0.000478	0.000842	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—HRAS—head and neck cancer	0.000478	0.000842	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—PIK3CA—head and neck cancer	0.000477	0.00084	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—HRAS—head and neck cancer	0.000476	0.000837	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—HRAS—head and neck cancer	0.000474	0.000833	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—PIK3CA—head and neck cancer	0.000473	0.000832	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—AKT1—head and neck cancer	0.000472	0.00083	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—PIK3CA—head and neck cancer	0.000471	0.000829	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—head and neck cancer	0.000467	0.000821	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—PTEN—head and neck cancer	0.000465	0.000818	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—AKT1—head and neck cancer	0.000464	0.000817	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—BCL2L1—head and neck cancer	0.000456	0.000803	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—AKT1—head and neck cancer	0.000452	0.000795	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—VEGFA—head and neck cancer	0.000448	0.000788	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—head and neck cancer	0.000447	0.000786	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—PIK3CA—head and neck cancer	0.000446	0.000784	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—HRAS—head and neck cancer	0.000446	0.000784	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—head and neck cancer	0.000446	0.000784	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—HRAS—head and neck cancer	0.000446	0.000784	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—AKT1—head and neck cancer	0.000444	0.000782	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—STAT3—head and neck cancer	0.000443	0.00078	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—HRAS—head and neck cancer	0.000442	0.000777	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—HRAS—head and neck cancer	0.000438	0.00077	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—HRAS—head and neck cancer	0.000436	0.000767	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PIK3CA—head and neck cancer	0.000427	0.000751	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—AKT1—head and neck cancer	0.000427	0.000751	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—AKT1—head and neck cancer	0.000424	0.000747	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—MAPK3—head and neck cancer	0.000424	0.000745	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—head and neck cancer	0.000422	0.000743	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—AKT1—head and neck cancer	0.000422	0.000743	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—AKT1—head and neck cancer	0.00042	0.000739	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—AKT1—head and neck cancer	0.000418	0.000736	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—STAT3—head and neck cancer	0.000416	0.000732	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—HRAS—head and neck cancer	0.000412	0.000726	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—head and neck cancer	0.000412	0.000725	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—MAPK1—head and neck cancer	0.000403	0.000709	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GRP—head and neck cancer	0.000398	0.000701	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—MAPK3—head and neck cancer	0.000397	0.000699	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—head and neck cancer	0.000395	0.000694	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—AKT1—head and neck cancer	0.000393	0.000692	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—head and neck cancer	0.000393	0.000692	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—AKT1—head and neck cancer	0.000393	0.000692	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NOTCH1—head and neck cancer	0.000392	0.000689	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—AKT1—head and neck cancer	0.00039	0.000686	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STAT6—head and neck cancer	0.000387	0.000681	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—AKT1—head and neck cancer	0.000386	0.00068	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—AKT1—head and neck cancer	0.000385	0.000677	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—MAPK1—head and neck cancer	0.000378	0.000665	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—EGFR—head and neck cancer	0.000378	0.000665	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	0.000377	0.000663	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CASP8—head and neck cancer	0.000373	0.000657	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	0.000372	0.000654	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—AKT1—head and neck cancer	0.000364	0.000641	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	0.000357	0.000629	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CDH1—head and neck cancer	0.000354	0.000623	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000352	0.00062	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—head and neck cancer	0.000348	0.000613	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—YAP1—head and neck cancer	0.000342	0.000602	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—TP53—head and neck cancer	0.000338	0.000595	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—PIK3CA—head and neck cancer	0.000328	0.000577	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—BCL2—head and neck cancer	0.00032	0.000563	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—UROD—head and neck cancer	0.000314	0.000553	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—HRAS—head and neck cancer	0.000304	0.000534	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTGS2—head and neck cancer	0.000291	0.000512	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NOTCH1—head and neck cancer	0.000274	0.000483	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—AKT1—head and neck cancer	0.000268	0.000472	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BCL2L1—head and neck cancer	0.000266	0.000468	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PTEN—head and neck cancer	0.000265	0.000467	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PTEN—head and neck cancer	0.000255	0.000448	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTEN—head and neck cancer	0.000254	0.000446	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—STAT3—head and neck cancer	0.000227	0.000399	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—MAPK3—head and neck cancer	0.000227	0.000399	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOTCH1—head and neck cancer	0.00022	0.000388	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CASP8—head and neck cancer	0.000217	0.000382	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MAPK3—head and neck cancer	0.000217	0.000381	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—MAPK1—head and neck cancer	0.000216	0.000379	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EGFR—head and neck cancer	0.000216	0.000379	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDH1—head and neck cancer	0.000215	0.000378	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—EGFR—head and neck cancer	0.000207	0.000364	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MAPK1—head and neck cancer	0.000206	0.000363	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EGFR—head and neck cancer	0.000206	0.000363	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL2—head and neck cancer	0.000189	0.000332	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PIK3CA—head and neck cancer	0.000187	0.000329	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BCL2—head and neck cancer	0.000186	0.000328	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCND1—head and neck cancer	0.000184	0.000324	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PIK3CA—head and neck cancer	0.00018	0.000316	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PIK3CA—head and neck cancer	0.000179	0.000315	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTEN—head and neck cancer	0.000178	0.000313	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—HRAS—head and neck cancer	0.000173	0.000305	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HRAS—head and neck cancer	0.000166	0.000293	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HRAS—head and neck cancer	0.000166	0.000291	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL2—head and neck cancer	0.000164	0.000289	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTGS2—head and neck cancer	0.000164	0.000288	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—VEGFA—head and neck cancer	0.00016	0.000282	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—STAT3—head and neck cancer	0.000159	0.000279	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PTEN—head and neck cancer	0.000154	0.000272	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOTCH1—head and neck cancer	0.000154	0.000271	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—AKT1—head and neck cancer	0.000153	0.000269	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MAPK3—head and neck cancer	0.000152	0.000267	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AKT1—head and neck cancer	0.000147	0.000258	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKT1—head and neck cancer	0.000146	0.000257	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MAPK1—head and neck cancer	0.000144	0.000254	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EGFR—head and neck cancer	0.000144	0.000254	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTEN—head and neck cancer	0.000143	0.000251	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—STAT3—head and neck cancer	0.000138	0.000243	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MAPK3—head and neck cancer	0.000132	0.000232	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NAT2—head and neck cancer	0.00013	0.00023	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—STAT3—head and neck cancer	0.000128	0.000224	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MAPK1—head and neck cancer	0.000126	0.000221	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EGFR—head and neck cancer	0.000126	0.000221	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CA—head and neck cancer	0.000125	0.00022	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MAPK3—head and neck cancer	0.000122	0.000214	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—head and neck cancer	0.000121	0.000213	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MAPK1—head and neck cancer	0.000116	0.000204	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGFR—head and neck cancer	0.000116	0.000204	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HRAS—head and neck cancer	0.000116	0.000204	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—DPYD—head and neck cancer	0.000114	0.000201	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CA—head and neck cancer	0.000109	0.000192	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—YAP1—head and neck cancer	0.000109	0.000191	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL2—head and neck cancer	0.000106	0.000187	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCND1—head and neck cancer	0.000103	0.000182	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT1—head and neck cancer	0.000102	0.00018	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HRAS—head and neck cancer	0.000101	0.000177	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CA—head and neck cancer	0.000101	0.000177	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTEN—head and neck cancer	9.99e-05	0.000176	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HRAS—head and neck cancer	9.31e-05	0.000164	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VEGFA—head and neck cancer	9.02e-05	0.000159	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STAT3—head and neck cancer	8.93e-05	0.000157	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT1—head and neck cancer	8.9e-05	0.000157	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAPK3—head and neck cancer	8.53e-05	0.00015	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT1—head and neck cancer	8.22e-05	0.000145	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAPK1—head and neck cancer	8.12e-05	0.000143	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGFR—head and neck cancer	8.12e-05	0.000143	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CA—head and neck cancer	7.05e-05	0.000124	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—head and neck cancer	6.82e-05	0.00012	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TYMS—head and neck cancer	6.52e-05	0.000115	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HRAS—head and neck cancer	6.52e-05	0.000115	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTM1—head and neck cancer	6.44e-05	0.000113	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GPX1—head and neck cancer	6.17e-05	0.000109	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP1A1—head and neck cancer	6.11e-05	0.000107	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT1—head and neck cancer	5.76e-05	0.000101	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS2—head and neck cancer	3.63e-05	6.39e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTEN—head and neck cancer	3.17e-05	5.58e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CA—head and neck cancer	2.24e-05	3.93e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKT1—head and neck cancer	1.83e-05	3.21e-05	CbGpPWpGaD
